FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Chard Daniel R 2. Issuer Name and Ticker or Trading Symbol MEDIFAST INC [ MED ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chairman & CEO
(Last)         (First)         (Middle)
C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR
3. Date of Earliest Transaction (MM/DD/YYYY)
6/11/2021
(Street)
BALTIMORE, MD 21202
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  6/11/2021    S    1847 (1) D $287.4071 (2) 139479  D   
Common Stock  6/11/2021    S    3264 (1) D $288.2118 (3) 136215  D   
Common Stock  6/11/2021    S    1563 (1) D $289.301 (4) 134652  D   
Common Stock  6/11/2021    S    761 (1) D $290.8758 (5) 133891  D   
Common Stock  6/11/2021    S    201 (1) D $291.6085 (6) 133690  D   
Common Stock  6/11/2021    S    400 (1) D $293.1144 (7) 133290  D   
Common Stock  6/14/2021    S    521 (1) D $278.1405 (8) 132769  D   
Common Stock  6/14/2021    S    2267 (1) D $279.5603 (9) 130502  D   
Common Stock  6/14/2021    S    1907 (1) D $280.3029 (10) 128595  D   
Common Stock  6/14/2021    S    1038 (1) D $281.4428 (11) 127557  D   
Common Stock  6/14/2021    S    303 (1) D $282.0594 (12) 127254  D   
Common Stock  6/14/2021    S    300 (1) D $283.6665 (13) 126954  D   
Common Stock  6/14/2021    S    100 (1) D $284.65  126854  D   
Common Stock  6/14/2021    S    100 (1) D $285.7436 (14) 126754  D   
Common Stock  6/14/2021    S    100 (1) D $287.7766 (15) 126654  D   
Common Stock  6/14/2021    S    343 (1) D $289.2819 (16) 126311  D   
Common Stock  6/14/2021    S    100 (1) D $291.00  126211  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The shares are sold pursuant to a 10b5-1 Plan entered into by the Reporting Person on March 2, 2021.
(2)  This transaction was executed in multiple trades at prices ranging from $286.86 USD to $287.85 USD inclusive; the price reported above reflects theweighted average sale price.
(3)  This transaction was executed in multiple trades at prices ranging from $287.86 USD to $288.53 USD inclusive; the price reported above reflects the weighted average sale price.
(4)  This transaction was executed in multiple trades at prices ranging from $288.92 USD to $289.88 USD inclusive; the price reported above reflects theweighted average sale price.
(5)  This transaction was executed in multiple trades at prices ranging from $290.25 USD to $291.16 USD inclusive; the price reported above reflects theweighted average sale price.
(6)  This transaction was executed in multiple trades at prices ranging from $291.30 USD to $291.74 USD inclusive; the price reported above reflects theweighted average sale price.
(7)  This transaction was executed in multiple trades at prices ranging from $292.67 USD to $293.32 USD inclusive; the price reported above reflects theweighted average sale price.
(8)  This transaction was executed in multiple trades at prices ranging from $277.85 USD to $278.83 USD inclusive; the price reported above reflects theweighted average sale price.
(9)  This transaction was executed in multiple trades at prices ranging from $278.85 USD to $279.84 USD inclusive; the price reported above reflects theweighted average sale price.
(10)  This transaction was executed in multiple trades at prices ranging from $279.85 USD to $280.83 USD inclusive; the price reported above reflects theweighted average sale price.
(11)  This transaction was executed in multiple trades at prices ranging from $281.00 USD to $281.94 USD inclusive; the price reported above reflects theweighted average sale price.
(12)  This transaction was executed in multiple trades at prices ranging from $282.00 USD to $282.10 USD inclusive; the price reported above reflects theweighted average sale price.
(13)  This transaction was executed in multiple trades at prices ranging from $283.45 USD to $284.00 USD inclusive; the price reported above reflects theweighted average sale price.
(14)  This transaction was executed in multiple trades at prices ranging from $285.65 USD to $286.01 USD inclusive; the price reported above reflects theweighted average sale price.
(15)  This transaction was executed in multiple trades at prices ranging from $287.68 USD to $287.89 USD inclusive; the price reported above reflects theweighted average sale price.
(16)  This transaction was executed in multiple trades at prices ranging from $289.00 USD to $289.49 USD inclusive; the price reported above reflects theweighted average sale price.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Chard Daniel R
C/O MEDIFAST, INC.
100 INTERNATIONAL DRIVE, 18TH FLOOR
BALTIMORE, MD 21202
X
Chairman & CEO

Signatures
/s/ Jason L. Groves, attorney-in-fact 6/15/2021
**Signature of Reporting Person Date
Medifast (NYSE:MED)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Medifast Charts.
Medifast (NYSE:MED)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Medifast Charts.